Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

162
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
162
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

724
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
724
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Aging01:26

Aging

545
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
545
The Effect of Aging on Tissues01:19

The Effect of Aging on Tissues

3.1K
Several body functions deteriorate with age. The external signs of aging are easily identifiable. For example, the skin becomes dry, less elastic, and thins out, forming wrinkles. The skin of the face begins to appear looser due to a decrease in the levels of elastic and collagen fibers in the connective tissue. Additionally, melanin production in the hair follicle decreases with age, resulting in gray hair. Moreover, the senses of sight and hearing decline, so glasses and hearing aids may...
3.1K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

722
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
722

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

mTOR drives cerebrovascular dysfunction and blood-brain barrier breakdown in a model of Alzheimer's disease with cerebral amyloid angiopathy.

bioRxiv : the preprint server for biology·2026
Same author

A Non-Canonical Role for Hepatocyte MLKL in Promoting Mitochondrial Dysfunction and Senescence in the Aging Liver.

Aging cell·2026
Same author

MeLSI: Metric Learning for Statistical Inference in microbiome community composition analysis.

mSystems·2026
Same author

Introduction to the special issue on the impact of climate change and air quality on human aging.

The journals of gerontology. Series A, Biological sciences and medical sciences·2026
Same author

A need for pragmatism in preclinical aging and longevity research.

Nature aging·2026
Same author

In memoriam: Thomas Eugene Johnson.

GeroScience·2026

Related Experiment Video

Updated: Jan 4, 2026

Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

22.1K

mTOR drives cerebrovascular, synaptic, and cognitive dysfunction in normative aging.

Candice E Van Skike1,2, Ai-Ling Lin3, Raquel Roberts Burbank1

  • 1Department of Cellular and Integrative Physiology, Barshop Institute for Longevity and Aging Studies, University of Texas Health San Antonio, San Antonio, Texas.

Aging Cell
|November 7, 2019
PubMed
Summary

Targeting the mechanistic/mammalian target of rapamycin (mTOR) pathway can improve brain function in aging. Inhibiting mTOR in aged rats reversed cognitive decline and restored cerebral blood flow, suggesting therapeutic potential for age-related cognitive impairment.

Keywords:
agingbrain vasculaturecerebral blood flowcognitive declinefunctional MRImTOR

More Related Videos

Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach
10:13

Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach

Published on: February 14, 2014

14.1K
A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis
05:12

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis

Published on: November 22, 2024

1.3K

Related Experiment Videos

Last Updated: Jan 4, 2026

Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

22.1K
Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach
10:13

Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach

Published on: February 14, 2014

14.1K
A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis
05:12

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis

Published on: November 22, 2024

1.3K

Area of Science:

  • Neuroscience
  • Gerontology
  • Vascular Biology

Background:

  • Age-related cerebrovascular dysfunction and cognitive decline are common but poorly understood.
  • Reduced cerebral blood flow is an early indicator in Alzheimer's disease (AD) pathogenesis.
  • The mechanistic/mammalian target of rapamycin (mTOR) pathway is implicated in AD and atherosclerosis-related cognitive impairment.

Purpose of the Study:

  • To investigate the role of mTOR in cerebrovascular dysfunction and cognitive decline during normal aging.
  • To determine if mTOR inhibition can ameliorate age-related cognitive and cerebrovascular deficits.

Main Methods:

  • Utilized behavioral tests and MRI-based functional imaging in aged rats.
  • Employed biochemical and immunohistochemical analyses of brain tissue.
  • Administered chronic mTOR inhibition using rapamycin.

Main Results:

  • mTOR inhibition with rapamycin improved learning and memory in aged rats.
  • Rapamycin treatment prevented neurovascular uncoupling and restored cerebral perfusion.
  • mTOR inhibition counteracted age-related decreases in synaptic and vascular density in the hippocampus and cortex.

Conclusions:

  • mTOR drives cerebrovascular, neuronal, and cognitive deficits associated with normative aging.
  • mTOR inhibitors show potential for treating age-related cognitive decline and cerebrovascular dysfunction.
  • Targeting mTOR may offer a strategy to prevent the initiation and progression of Alzheimer's disease.